{"id":"W3014880052","doi":"10.1080/13543784.2020.1751121","title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Clinical trial; Phases of clinical research; Tofacitinib; Pharmacology; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004662839,0.0002054638,0.0003413428,0.0002289441,0.0001436353,0.0004624951,0.0002993571,0.000534404,0.00867918],"category_scores_gemma":[0.0006550027,0.00006076487,0.0003635393,0.0002342037,0.0002342511,0.0004359598,0.0002430434,0.001075582,0.00288231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003388152,"about_ca_system_score_gemma":0.0004836042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002220085,"about_ca_topic_score_gemma":0.001206587,"domain_scores_codex":[0.9997618,0.00005797135,0.00002670691,0.00002691289,0.00009312521,0.00003363662],"domain_scores_gemma":[0.9995829,0.0001117306,0.0001486469,0.00001453324,0.00007440158,0.00006783669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007808157,0.000128236,0.001130819,0.002483737,0.00008721372,0.0006909254,0.00003814084,0.0002230409,0.005432549,0.003541923,0.1391319,0.8463306],"study_design_scores_gemma":[0.000523039,0.0008569388,0.003371002,0.001253424,0.00009467846,0.003113171,0.00002807817,0.0001862024,0.00186358,0.00165708,0.9870388,0.00001402123],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01914347,0.8440138,0.002268939,0.03848732,0.005859023,0.0002347476,0.001783302,0.0003247597,0.08788475],"genre_scores_gemma":[0.1776419,0.6848627,0.005096383,0.0407827,0.01160413,0.0004050815,0.004176376,0.00008942749,0.07534141],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00867918,"threshold_uncertainty_score":0.02903473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08566006386425828,"score_gpt":0.41308605949262,"score_spread":0.3274259956283617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}